Heparin is the in the greatest degr...

Heparin is the in the greatest degree widely used agent for prevention and treatment of clotting disorders. Since its discovery in 1916 heparin has become the anticoagulant of choice to stop concretion formation in the arteries of patients with cardiovascular disease and in patients who are undergoing cardiac revascularization, open-heart surgery and coronary angioplasty. (1) Heparin also is used to treat arterial and venous clotting and hinder formation of venous clots in patients who require neurosurgery or orthopedic surgery and in trauma cases.

Despite its use to interrupt the formation of thrombus during and after surgery adverse thrombotic complications associated with heparin are not infrequent Heparin-induced thrombocytopenia (HIT) is a life- and limb-threatening reaction to heparin characterized at platelet level decreases and thrombus formation. There are many causes of thrombocytopenia unrelated to HIT, for a like reason this condition easily can move unnoticed. Failure to recognize HIT can lead to serious patient complications. This article reviews the immune basis of HIT, clinical manifestations, and the character of nurses in the diagnosis and treatment of HIT.

IMMUNE BASIS OF HIT

Heparin is prepared commercially from animal sources consisting of glycosaminoglycan atoms in a weight range from 10000 daltons (d) to 20000 d (2) proper to the large molecule size and repetitive chemical form heparin lends itself easily to the formation of immune complexe as it is as those typical of HIT. cheap molecular weight heparin (LMWH) is derived from regular (ie, unfractionated) heparin in consequence of chemical or physical means, of that kind as filtration. The LMWH atom ranges from 3,000 d to 10000 d (23)

Heparin-induced thrombocytopenia is an immune-mediated reaction to heparin that often results in the formation of arterial and venous concretes with associated serious clinical symptomatology and plane death. Among patients receiving either unfractionated heparin or LMWH by way of any route, approximately 5% will expand an immune reaction typical of HIT, and at least half of these, representing more than 360000 individuals annually, will have clinically evident HIT-associated thrombosis. (3-6) coagulate formation is the most serious inference of HIT. Despite significant platelet decreases and, as a common thing [i]or[/i] matter thrombocytopenia, it is not everyday for patients to experience signs of hemorrhage, spontaneous bleeding, and petechiae. Heparin-induced thrombocytopenia creates a hypercoagulable state, and clotting remains the primary health threat, equable in cases where thrombocytopenia is methodical (6)

The initiation of coagulate formation in patients with HIT begins with the creation of a unique multimolecular entangled composed of heparin bound to platelet factor 4 (PF4) a protein originating from platelets. The combination of heparin and PF4 creates an attractive environment for the posterior binding of antibody immunoglobulin G (IgG). After attaching to the multimolecular intricate web IgG is placed in finish proximity to the Fc receptor, a platelet surface protein that assists as the trigger for platelet activation and the resultant release of platelet-derived prothrombotic microparticles (Figure 1) (36-8)

[FIGURE 1 OMITTED]

In hospital settings, thrombocytopenia and thrombosis unrelated to HIT repeatedly are observed. The common event of platelet count decreases coupl with the seeming contradiction of a clotting medication, heparin, producing an immune-mediated thrombocytopenic state l physicians to dismiss the actual existence of HIT for years. Increasingly, sensitive laboratory trials have given practitioners a greater appreciation for the existence and inferences of the syndrome. (6,8) Today, HIT is accepted widely as a well-defined clinicopathological syndrome Acceptance of HIT syndrome is based in part in succession a specific clinical definition of its presentation and the availability of laboratory criterions capable of detecting even virtuous titers of HIT antibodies. (6)

CLINICAL MANIFESTATIONS

The clinical diagnosis of HIT hangs both on the timing and amount of platelet even decrease. Typically, patients with HIT will disentangle thrombocytopenia five to 14 days after the initiation of heparin dosing; however, about individuals will show a 30% to 50% ear-ring in platelet count within the same five to 14 days and still have an absolute platelet consider higher than the level defined as thrombocytopenic. Although platelet cast up less than 150,000 per [mmsup3] is a usual occurrence with HIT, it does not present itself universally and, therefore, may not be considered an absolute diagnostic requirement. In those patients for whom significant platelet estimate decreases do occur, careful monitoring is important because it is possible for computes as low as 80,000 by [mm.sup.3] to 30,000 per [mmsup3] or lower to offer (3,6) For patients previously expos to heparin, platelet evens will decrease more rapidly and become clinically evident before the usually combated five-day period. It is possible for an patients previously exposed to heparin to perform the operations indicated in thrombocytopenia within hours of heparin administration. This rapid platelet decrease indicates an anamnestic response (ie, a rapid immune answer to new antigens by an already primed immune system) (34)